Skip to main content
OpenTrials
Completed

NCT Number: NCT04683562

Netrin-1 and Placenta Accreta

Netrin-1 is a secreted protein, which was first identified as a neuronal guidance factor. It is expressed in a multitude of tissues as pancreas, lung, breast, and placenta. Netrin-1 is a multifunctional protein, involved in cell polarity, adhesion, angiogenesis, apoptosis, migration, morphogenesis, and differentiation of various cell types. Most of netrin-1 activity occur through signaling pathways induced by its two main receptors, DCC (deleted in colorectal cancer) and UNC5H (uncoordinated-5 homolog). Its receptors have been linked to the processes of apoptosis and angiogenesis. In absence of netrin-1, DCC and UNC5H receptors lead to apoptosis. In contrary, in presence of netrin-1, receptors transduce molecular cascades leading to proliferation, differentiation and migration of the cells. Netrin-1 has been involved in the pathogenesis of multiple diseases, as diabetes, cardiovascular diseases, and cancer. Serum Netrin-1 levels were high in preeclamptic patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Woman's Health Hospital

Asyut, 71111, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 20-40 years.
  • Singleton pregnancy.
  • Women with suspicion of PA by two-dimensional (2D) gray scale imaging and color Doppler flow mapping

Exclusion criteria

  • Multiple pregnancy,
  • Fetal anomalies,
  • Preterm premature rupture of membranes, or infection
  • Any medical disorders, such as thyroid dysfunction, hypertension, and gestational diabetes
  • Patients with known bleeding disorders or on anticoagulant therapy.

Treatment and study plan

Pregnant women at 28-32 weeks

Other

Pregnant women at gestational age 28-32 weeks

at delivery

Other

women delivered at term

Primary outcomes

  1. Placental Netrin-1 level

    Time frame: 4 weeks

    will be measured by using enzyme-linked immunosorbent assay (ELİSA) in placental homogenate

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

The Implication of Placental Netrin-1 Receptor DCC in the Pathophysiology of Placenta Accreta

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 24, 2020
Registry last updated
Aug 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.